Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs
PLOS One · 2025
DOI: 10.1371/journal.pone.0325695 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Camilla Pegram und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pathobiology and Population Sciences, The Royal Veterinary College, Hatfield, United Kingdom. Hauptthemen laut MEDLINE: Pyridazines, Dog Diseases, Heart Murmurs, Heart Failure. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dogs Trust.
Abstract (Originalsprache)
Target trial emulation applies design principles from randomised controlled trials (RCTs) to the analysis of observational data, potentially replicating RCT results in real-world settings. The EPIC trial reported that pimobendan delays the onset of congestive heart failure (CHF) and extends survival in dogs with preclinical degenerative mitral valve disease (DMVD). The current study aimed to explore the extent to which target trial emulation approximates the EPIC trial results in a primary-care setting. Grade IV/VI murmur diagnosis was defined as the treatment intervention stage. There were 928 dogs ≥ 6 years and ≤ 15 kg at first grade IV/VI murmur diagnosis recorded from January 1, 2016, to December 31, 2018 in the VetCompass database included in the study. A causal inference “target trial emulation” approach using VetCompass anonymised clinical data was designed to replicate the EPIC trial with adaptation for a primary-care setting and to address immortal time bias, confounding bias and loss to follow-up. After bias adjustments to establish causal effects using observational data, the 5-year CHF cumulative incidence was lower in dogs prescribed pimobendan (34.1%, 95% CI 26.5–42.0) than dogs not prescribed pimobendan (56.3%, 95% CI 52.8–59.8). Dogs prescribed pimobendan had 311 fewer days of health lost to CHF (95% CI 224–395 days) within 5 years. Dogs prescribed pimobendan lived longer (adjusted mean survival time 1051 days, 95% CI 967–1125) than dogs not prescribed pimobendan (905 days, 95% CI 871–940 days). This study demonstrates that target trial emulation within veterinary research can replicate findings from RCTs. Clinically, the current findings suggest that preclinical grade IV murmur diagnosis may offer an appropriate intervention stage to begin pimobendan therapy in dogs with presumed DMVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pathobiology and Population Sciences, The Royal Veterinary College, Hatfield, United Kingdom.
- University College London, Department of Statistical Science, London, United Kingdom.
- Comparative Biomedical Sciences, The Royal Veterinary College, Hatfield, Herts, United Kingdom.
- Clinical Science and Services, The Royal Veterinary College, Hatfield, United Kingdom.
- Professional Services, The Royal Veterinary College, Royal College Street, London, United Kingdom.
- Department of Intensive Care, Erasmus Medical Center, Rotterdam, the Netherlands.
ORCID-Profile: Camilla Pegram, Carmen A T Reep
Förderung
- Dogs Trust
Zitieren
APA
Pegram, C., Diaz-Ordaz, K., Brodbelt, D. C., Chang, Y. M., Boswood, A., Wilshaw, J., Reep, C. A. T., Balling, S., Sahota, J., Church, D. B., & O'Neill, D. G. (2025). Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs. PLOS One. https://doi.org/10.1371/journal.pone.0325695
Vancouver
Pegram C, Diaz-Ordaz K, Brodbelt DC, Chang YM, Boswood A, Wilshaw J, et al. Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs. PLOS One. 2025. doi:10.1371/journal.pone.0325695
BibTeX
@article{Pegram2025,
author = {Pegram, Camilla and Diaz-Ordaz, Karla and Brodbelt, Dave C and Chang, Yu-Mei and Boswood, Adrian and Wilshaw, Jenny and Reep, Carmen A T and Balling, Sarah and Sahota, Jaya and Church, David B and O'Neill, Dan G},
title = {Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0325695}
}
EUVIMED